Kelun-Biotech Advances Asthma Treatment with NMPA IND Approval for Bispecific Antibody
Event summary
- Kelun-Biotech and Harbour BioMed received NMPA approval for the IND application of SKB575/HBM7575, a bispecific antibody targeting asthma.
- SKB575/HBM7575 is designed to block TSLP and an undisclosed target, aiming for broader inflammation control than single-target therapies.
- The drug has already entered Phase I trials for atopic dermatitis, with the first participant dosed previously.
- Kelun-Biotech leads global development and commercialization under a collaboration agreement with Harbour BioMed.
The big picture
The approval of SKB575/HBM7575 underscores the growing focus on bispecific antibodies for chronic immune-mediated diseases. With asthma affecting over 300 million people globally, the need for more effective long-acting treatments is critical. Kelun-Biotech's leadership in this space positions it as a key player in respiratory disease therapeutics.
What we're watching
- Clinical Progress
- The pace at which SKB575/HBM7575 advances through Phase I trials for asthma will determine its potential as a best-in-class therapy.
- Market Differentiation
- Whether the dual-target mechanism of SKB575/HBM7575 can deliver superior inflammation control compared to existing treatments.
- Commercial Strategy
- How Kelun-Biotech plans to leverage its global development and commercialization lead in positioning SKB575/HBM7575 for market entry.
Related topics